4H-<1,2,4>-triazolo<4,3-a><1,5>benzodiazepin-5(6H)-one | 137731-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并二氮卓类
• 英文名称: 4H-<1,2,4>-triazolo<4,3-a><1,5>benzodiazepin-5(6H)-one
• 英文别名: 5,6-dihydro-4H-[1,2,4]-triazolo-[4,3-a][1,5]benzodiazepin-5-one；4,6-dihydro-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-one
• CAS: 137731-06-7
• 化学式: C₁₀H₈N₄O
• 分子量: 200.2
• InChiKey: HGTGZFQXRMBAAS-UHFFFAOYSA-N

物化性质

• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4H-<1,2,4>-triazolo<4,3-a><1,5>benzodiazepin-5(6H)-one 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 生成 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine
  参考文献：
  名称：

  Tricyclic diazepine vasopressin antagonists and oxytocin antagonists

  摘要：

  三环二氮杂苯的化学式为：##STR1## 其中A、B、D、E、F、Y和Z在规范中有定义，这些化合物具有抗利尿激素和催产素拮抗活性。

  公开号：

  US05736540A1
• 作为产物：
  描述：

  甲酰肼 、 2-(Dimethylamino)-1,3-dihydro-2H-1,5-benzodiazepin-2-one 在 溶剂黄146 作用下， 以 various solvent(s) 为溶剂， 反应 2.0h， 以54%的产率得到4H-<1,2,4>-triazolo<4,3-a><1,5>benzodiazepin-5(6H)-one
  参考文献：
  名称：

  1,5-Benzodiazepines IX. A new route to substituted 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines with analgesic and/or anti-inflammatory activities

  摘要：

  A new two-step synthetic pathway to substituted 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines 2a-p is described. The cyclocondensation of (dimethylamino)benzodiazepinone 1a with hydrazides afforded triazolobenzodiazepinones 5 which in turn reacted with suitable primary or secondary amines, in the presence of titanium tetrachloride, to give the desired 5-amino-derivatives 2a-p. When compounds 5 were treated with the Lawesson's reagent thiolactams 6 were obtained, which then reacted with sodium hydride and proper alkyl halides to yield 5-(alkylthio)derivatives 7a-d. Compounds 2a-h, j-p, and 7a-d were tested for their analgesic and anti-inflammatory activities, as well as for their acute toxicity and gross behavioral effects. The analgesic activity appeared noteworthy in the writhing test, where fifteen compounds were more effective than both the reference drugs acetylsalicylic acid and dipyrone, but was less evident in the hot plate test. An anti-inflammatory activity, lower than that of indomethacin but reaching the level of statistical significance, was displayed in the carrageenin-induced edema assay by five of the nineteen test compounds.

  DOI：

  10.1016/0223-5234(91)90144-c

文献信息

• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05536718A1

  公开（公告）日：1996-07-16

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  三环化合物的一般公式I：##STR1##，如本文所述，具有V.sub.1和/或V.sub.2受体的拮抗剂活性，并在体内表现出抗利尿激素拮抗剂活性，使用这些化合物治疗以肾水过度重吸收为特征的疾病的方法，以及制备这些化合物的方法。
• [EN] 1,2,4 TRIAZOLO [4, 3 -A] [1,5] BENZODIAZEPIN-5 (6H) -ONES AS AGONISTS OF THE CHOLECYSTOKININ-1 RECEPTOR (CCK-IR)<br/>[FR] 1,2,4 TRIAZOLO[4,3-A][1,5] BENZODIAZÉPIN-5(6H)-ONES UTILISÉES COMME AGONISTES DU RÉCEPTEUR DE LA CHOLÉCYSTOKININE-1 (CCK-1R)
  申请人：PFIZER

  公开号：WO2010067233A1

  公开（公告）日：2010-06-17

  This invention relates to CCK-1 R agonists of Formula (I) wherein R1-R5 and X are as defined in the specificiation, as well as pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity, type 2 diabetes and associated diseases.

  这项发明涉及到式（I）中的CCK-1 R激动剂，其中R1-R5和X如规范中所定义，以及含有这些化合物的药物组合物和这些化合物和组合物的使用方法。这些化合物在治疗肥胖症、2型糖尿病及相关疾病方面是有用的。
• Tricyclic diazepines vasopressin and oxytocin antagonists
  申请人：American Cyanamid Company

  公开号：EP0636625B1

  公开（公告）日：1999-01-27
• TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS
  申请人：American Cyanamid Company

  公开号：EP0804438A1

  公开（公告）日：1997-11-05
• TRICYCLIC VASOPRESSIN ANTAGONISTS
  申请人：American Cyanamid Company

  公开号：EP0805813B1

  公开（公告）日：2002-05-15